Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer—A Review of the Literature

The latest and newest discoveries for advanced and metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer are the three cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) in association with endocrine therapy (ET). However, even if t...

Descripción completa

Detalles Bibliográficos
Autores principales: Stanciu, Ioana-Miruna, Parosanu, Andreea Ioana, Orlov-Slavu, Cristina, Iaciu, Ion Cristian, Popa, Ana Maria, Olaru, Cristina Mihaela, Pirlog, Cristina Florina, Vrabie, Radu Constantin, Nitipir, Cornelia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000620/
https://www.ncbi.nlm.nih.gov/pubmed/36900131
http://dx.doi.org/10.3390/diagnostics13050987

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000620/
https://www.ncbi.nlm.nih.gov/pubmed/36900131
http://dx.doi.org/10.3390/diagnostics13050987

Ejemplares similares